Representative Matters

Financing

Among our recent financing matters, we have represented:

  • Abilitech Medical, Inc., a company developing an exoskeleton to help people who have neuromuscular weakness in their arms, in a $2.3 million venture capital financing.
  • Amphora Medical Inc., a medical device manufacturer, in a $35 million Series B funding.
  • Aria CV, Inc., a company developing a medical device designed to improve the lives of patients living with the disease of pulmonary hypertension, in an $8 million venture capital financing.
  • Autonomix Medical, Inc., a privately held neural feedback device company, in a $2 million convertible note financing that converted to Series A preferred stock.
  • BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) in several underwritten, registered direct and PIPE offerings.
  • Bright Health, a health care insurance company, in an $80 million Series A funding.
  • Cardionomic, Inc., a medical device developer of a therapy to increase cardiac output, in a $20 million venture capital financing.
  • ClarVista Medical, Inc., a venture capital-backed company with products treating ophthalmic conditions, in a $14 million Series B preferred stock financing.
  • CRO Analytics, a clinical research company for the biopharmaceutical industry, on a Ben Franklin Partners Series A financing.
  • Gravie, Inc., a healthcare company in a $14 million Series C financing.
  • Innerspace Neuro Solutions Inc., a company developing a treatment for intracranial pressures, in a restructuring and simultaneous $2 million venture capital financing.
  • iotaMotion, Inc., a company developing robotics-assisted technologies for use in cochlear implantation and related ENT procedures, in a $2 million private financing.
  • Medical Transcription Billing, Corp. (NASDAQ: MTBC), a leading provider of proprietary, web-based electronic health records, practice management and mHealth solutions, in its initial public offering of 4.1 million shares of common stock at $5 per share.
  • Monteris Medical Corporation, a privately held neurosurgical device company, in a $34 million Series C financing.
  • NewSpring Capital, LP in connection with its $4 million Series B investment in RightCare, an industry leading medical technology company focused on improving patient outcomes and reducing readmissions.
  • Nuvaira, Inc., a privately held lung denervation company developing minimally invasive products to make breathing easier for patients suffering from obstructive lung diseases, in a $42 million venture financing.
  • OneOme LLC, a company offering a DNA test and resulting individualized reports that predict an individual’s response to drug therapy, in a $7 million private financings.
  • OrthoGenRx, a late-stage product development company focused on the commercialization of generic Class III orthopedic medical devices, in a Series C financing.
  • Pursuit Vascular, Inc., a privately held medical device company in a $5 million Series B financing.
  • ReliefBand Technologies LLC, a digital neurotechnology company that provides leading edge personalized medical treatment, in a $5 million Series A funding. 
  • ReShape Lifesciences, Inc., a company focused on the design, development and commercialization of transformative technologies to treat obesity and metabolic diseases, in its $18 million underwritten public offering.
  • Rosemark Capital, a private equity firm that partners with tech companies in bringing new ideas and solutions to market, in its $23.5 million Series C Funding of Jiff, an enterprise health benefits platform.
  • Rotation Medical, Inc., a venture capital-backed medical device company with products to treat rotator cuff disease, in a $27.6 million Series B preferred stock financing.
  • Spineology Inc., a medical technology company focused on next-generation spinal technology, in a $10 million convertible debenture financing.
  • SpineThera, Inc., a private company with sustained-release drug delivery products in a $5 million Series B financing.
  • Torax Medical, Inc., a venture capital-backed medical device company with products to treat gastro-esophageal reflux disease, in a $30 million Series D preferred stock financing.
  • Tornier N.V. (NASDAQ: TRNX), a premier high-growth extremities and biologics company, in its $210 million underwritten public offering.
  • Trice Medical, a pioneer in needle-based diagnostic and therapeutic technologies for orthopedics, in a Series B preferred stock financing.
  • Tryton Medical, Inc., a privately held stent company, in a $20 million Series BB financing.

Mergers and Acquisitions

Among our mergers and acquisitions matters, we have represented:

  • Biosante Pharmaceuticals, Inc. (NASDAQ: BPAX), a pharmaceutical company focused on reproductive health, in the following transactions:
    • Purchase of Cell Genesys, Inc.
    • Stock-for-stock merger with ANI Pharmaceuticals, including a Form S-4 registration statement in connection with the merger.
  • Caisson Interventional LLC, a medical technology company, in its acquisition by LivaNova.
  • CardioInsight, Inc., a medical device company specializing in cardiac mapping technology, in its sale to Medtronic, Inc. following Medtronic’s strategic investment in CardioInsight.
  • Enantigen Therapeutics, Inc., a privately held pharmaceutical company located at the Pennsylvania Biotechnology Center, in its acquisition by OnCore Biopharma, Inc., a biotechnology company focused on the research, development and commercialization of oral treatments for chronic hepatitis B virus (HBV) infection.
  • ev3 Inc. (NASDAQ: EVV), a global technology provider for specialists treating a wide range of vascular diseases and disorders, in its sale to Covidien for approximately $2.6 billion in cash, pursuant to a tender offer by Covidien.
  • Hemosphere, Inc., a privately held medical device company, it its sale to CryoLife, Inc.
  • Moda Technology Partners, Inc., a privately held software company focused on the growing need for effective automation and efficient regulatory compliance within the biopharmaceutical, consumer products, food processing and petrochemical industries, in the sale of all of its stock to Lonza, Inc., a Swiss publicly traded pharmaceutical company.
  • NeuWave Medical, Inc., a privately held medical device company that manufactures and markets minimally invasive soft-tissue microwave ablation systems, in the acquisition by Ethicon Endo-Surgery, Inc., a medical device company part of the Johnson & Johnson family of companies.
  • ReShape Lifesciences, Inc., a company focused on the design, development and commercialization of transformative technologies to treat obesity and metabolic diseases, in the following transactions:
    • Its stock acquisition of BarioSurg, Inc., valued at $28.3 million.
    • Its stock acquisition of ReShape Medical, Inc., valued at $60 million.
  • RestorGenex Corporation (OTCQX: RESX), a public specialty biopharmaceutical company, in its merger with Diffusion Pharmaceuticals, a privately held clinical stage biotechnology company.
  • Rotation Medical, Inc., a privately held device company with products to treat rotator cuff disease, in an acquisition by Smith & Nephew for $125 million in cash and up to $85 million in performance-based milestone payments.
  • superDimension, a private company based in Israel that develops minimally invasive interventional pulmonology devices, in its sale to Covidien for approximately $350 million.
  • The Chemistry Research Solution LLC, a chemistry and bioconjugation company, in its acquisition by Abzena plc (AIM: ABZA), a British life sciences technology company, for $15 million.
  • Tornier N.V. (NASDAQ: TRNX), a premier high-growth extremities and biologics company, in its:
    • Stock-for-stock merger with Wright Medical Group, Inc., including a Form S-4 registration statement in connection with the merger.
    • Acquisition of OrthoHelix Surgical Designs for approximately $135 million in a combination of cash and stock.
  • Torax Medical, Inc., a venture-capital backed medical device company with products to treat gastro-esophageal reflux disease, in a sale to Ethicon, a subsidiary of the Johnson & Johnson family of companies.
  • Uroplasty (NASDAQ: UPI), a global medical company, in its stock-for-stock merger with Vision-Sciences, Inc. (NASDAQ: VSCI), including a Form S-4 registration statement in connection with the merger.
  • Vios Medical, Inc., a medical technology company, in its sale to Murata Manufacturing Co., Ltd.
  • Virtual Radiologic Corporation (NASDAQ: VRAD), a global telemedicine company, in its sale to Providence Equity Partners for approximately $250 million.